Form 4: Monte Rosa Therapeutics Director Reports Stock Transactions

Ali Behbahani, a Director at Monte Rosa Therapeutics, Inc., reported transactions involving common stock on July 1, 2026, primarily through investment entities.

Summary

• Ali Behbahani, a Director of Monte Rosa Therapeutics, Inc. (GLUE), reported several transactions on July 1, 2026.
• A distribution of 1,000,000 shares of Common Stock was made by New Enterprise Associates 17, L.P. ('NEA 17') to its general partner and limited partners for no consideration.
• The reporting person, Behbahani, is a manager of NEA 17 GP, LLC, the general partner of NEA Partners 17, L.P., which is the general partner of NEA 17.
• Behbahani disclaims beneficial ownership of the 1,000,000 shares held by NEA 17, as he has no pecuniary interest.
• NEA Partners 17 received 15,000 shares of Common Stock from NEA 17's distribution.
• Behbahani also disclaims beneficial ownership of these 15,000 shares held by NEA Partners 17.
• NEA Partners 17 then distributed 15,000 shares of Common Stock for no consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It primarily clarifies ownership structures and distributions among investment entities rather than indicating new buying or selling activity by the director with direct financial intent.

Positives

• Director Ali Behbahani's beneficial ownership structure is clarified through these transactions.
• The transactions involved distributions for no consideration, indicating no direct cost to the entities involved.

Negatives

• The reporting person disclaims beneficial ownership for a significant number of shares (1,000,000 and 15,000), indicating a lack of direct control or financial interest.
• The complex structure of ownership through multiple entities (NEA 17, NEA 17 GP, NEA Partners 17) may obscure direct beneficial ownership.

Risks

• The disclaimer of beneficial ownership for a large number of shares could raise questions about the reporting person's true level of influence or financial stake in the company.
• The complexity of the ownership structure might lead to confusion regarding the ultimate beneficial owners of the securities.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• The reporting person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
• The reporting person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This filing details a distribution of shares among investment entities, which is a common practice for venture capital and private equity-backed companies transitioning to public status or managing their portfolios.

Related Party Transactions

• Distribution of 1,000,000 shares of Common Stock from NEA 17 to its general partner and limited partners.
• Distribution of 15,000 shares of Common Stock from NEA Partners 17 for no consideration.

Stakeholder Impact

• Shareholders: Increased transparency regarding the beneficial ownership structure of a director.
• Management: Clarification of reporting person's indirect holdings and disclaimers.

Key Dates

Keywords

SEC Form 4, Monte Rosa Therapeutics, GLUE, Ali Behbahani, Director, Beneficial Ownership, Stock Distribution, Common Stock, Insider Trading, SEC Filing